Adenocarcinoma News and Research

RSS

Adenocarcinoma is cancer that begins in cells that line certain internal organs and that have gland-like (secretory) properties.

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

The Pancreatic Cancer Action Network is pleased to announce that today ABRAXANE® was approved by the U.S. Food and Drug Administration (FDA) to treat metastatic pancreatic cancer.

7 Sep 2013

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute.

7 Sep 2013

Assay aids ALK fusion detection in lung adenonocarcinoma

A fully automated immunochemistry assay is highly sensitive and specific for detecting anaplastic lymphoma kinase fusion in primary lung adenocarcinomas, Chinese researchers report.

6 Sep 2013

Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC

Albumin-bound paclitaxel plus carboplatin is an effective and well-tolerated first-line treatment in patients with advanced non-small-cell lung cancer, irrespective of histology, study results show.

29 Aug 2013

Study compares spectrum of cancer-related gene mutations in two common types of cervical cancer

A new study has revealed marked differences in the genomic terrain of the two most common types of cervical cancer, suggesting that patients might benefit from therapies geared to each type's molecular idiosyncrasies.

26 Aug 2013

Seven researchers to receive grants from ASTRO to advance radiation oncology research

The American Society for Radiation Oncology (ASTRO) has selected seven (7) leading researchers who will receive a total of $675,000 in awards and grants to advance radiation oncology research.

23 Aug 2013

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

High mobility group A genes are highly expressed in all aggressive cancers studied to date. These genes encode the high mobility group A (HMGA) proteins. In other words, these genes provide the genetic “code” necessary to produce HMGA proteins.

8 Aug 2013

Specific pattern in lung tumor pathology is strong predictor of recurrence, says study

A new study by thoracic surgeons and pathologists at Memorial Sloan-Kettering Cancer Center shows that a specific pattern found in the tumor pathology of some lung cancer patients is a strong predictor of recurrence.

8 Aug 2013

Study reveals nearly 40% of tumors are caused by viruses

The results of a large-scale analysis of the association between DNA viruses and human malignancies suggest that many of the most common cancers are not associated with DNA viruses.

6 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

Research team receives NCI grant to develop precision therapies that kill cancer cells

A research team headed by Fred Hutchinson Cancer Research Center scientists Christopher Kemp, Ph.D., and Carla Grandori, M.D., Ph.D., has received a $4 million grant from the National Cancer Institute to develop precision therapies that selectively kill cancer cells while sparing normal, healthy tissue.

24 Jul 2013

Scientists develop histology expression predictor for most common types of lung cancer

Knowing what type of lung cancer a patient has is critical to determine which drug will work best and which therapies are safest in the era of personalized medicine. Key to making that judgment is an adequate tumor specimen for the pathologist to determine the tumor's histology, a molecular description of a tumor based on the appearance of cells under a microscope.

17 Jul 2013

Aflibercept drug shows minor added benefit for overall survival in colorectal cancer patients

The drug aflibercept (trade name: Zaltrap) has been approved in Germany since February 2013 in combination with a certain chemotherapy for adults with metastatic colorectal cancer in whom chemotherapy with oxaliplatin could not stop the disease from progressing.

12 Jul 2013

Prolonged exposure to low levels of air pollution boosts lung cancer risk

Prolonged exposure to particulate air pollution increases the risk of lung cancer (particularly adenocarcinoma) even at levels below the European Union limit values, according to one of the largest studies of its kind published in The Lancet Oncology.

11 Jul 2013

Study shows disrupted micronuclei may prove to be a valuable tool for detecting cancer

Scientists studying cancer development have known about micronuclei for some time. These erratic, small extra nuclei, which contain fragments or whole chromosomes that were not incorporated into daughter cells after cell division, are associated with specific forms of cancer and are predictive of poorer prognosis.

10 Jul 2013

Disrupted micronuclei might play more active role in carcinogenesis, new study finds

9 Jul 2013

Research suggests new models for study of Barrett's esophagus

Research focused on the regulation of the adult stem cells that line the gastrointestinal tract of Drosophila suggests new models for the study of Barrett's esophagus.

28 Jun 2013

Researchers say hCNT1 protein may affect cancer cells physiology, apart from transport function

The protein hCNT1, which plays a major role in nucleoside transport, may have other biological functions that may affect cancer cells physiology, apart from their transport function. This is the main conclusion of the new scientific work published on the journal Cell Death and Disease.

26 Jun 2013

Immunohistochemistry could be a reliable and cost-effective diagnostic approach for lung cancer

ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC). It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma that can benefit by the treatment of ALK-inhibitors.

26 Jun 2013

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.

26 Jun 2013

Adenocarcinoma News and Research

Further Reading

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

Assay aids ALK fusion detection in lung adenonocarcinoma

Albumin-bound paclitaxel has favorable risk–benefit profile in NSCLC

Study compares spectrum of cancer-related gene mutations in two common types of cervical cancer

Seven researchers to receive grants from ASTRO to advance radiation oncology research

High mobility group (HMG) genes and cancer: an interview with Dr. Linda Resar, Johns Hopkins University School of Medicine

Specific pattern in lung tumor pathology is strong predictor of recurrence, says study

Study reveals nearly 40% of tumors are caused by viruses

ImmunoGen reports net loss of $21.9 million in Q4 2013

Research team receives NCI grant to develop precision therapies that kill cancer cells

Scientists develop histology expression predictor for most common types of lung cancer

Aflibercept drug shows minor added benefit for overall survival in colorectal cancer patients

Prolonged exposure to low levels of air pollution boosts lung cancer risk

Study shows disrupted micronuclei may prove to be a valuable tool for detecting cancer

Disrupted micronuclei might play more active role in carcinogenesis, new study finds

Research suggests new models for study of Barrett's esophagus

Researchers say hCNT1 protein may affect cancer cells physiology, apart from transport function

Immunohistochemistry could be a reliable and cost-effective diagnostic approach for lung cancer

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News